Exercise, fitness, and cardiovascular disease risk in type 2 diabetes and the metabolic syndrome

被引:48
|
作者
Duncan G.E. [1 ]
机构
[1] Interdisciplinary Graduate Program in Nutritional Sciences, Department of Epidemiology, University of Washington, Seattle, WA 98195
关键词
Physical Activity; Metabolic Syndrome; Impaired Fasting Glucose; Diabetes Prevention Program; Cardiovascular Disease Risk Factor;
D O I
10.1007/s11892-006-0048-1
中图分类号
学科分类号
摘要
This article highlights research supporting the concept that increased physical activity and cardiorespiratory fitness attenuate risk of cardiovascular disease, type 2 diabetes, and the metabolic syndrome. Increased activity and fitness also attenuate risk of developing cardiovascular disease in persons who have type 2 diabetes or the metabolic syndrome. Although controversial, relationships between physical activity/physical fitness and type 2 diabetes/metabolic syndrome are largely independent of body weight. Thus, physical inactivity and poor cardiorespiratory fitness are not only important determinants of cardiovascular and metabolic diseases, but they can also be considered common features of these conditions, much like traditional risk factors such as obesity and insulin resistance. Copyright © 2006 by Current Science Inc.
引用
收藏
页码:29 / 35
页数:6
相关论文
共 50 条
  • [21] CARDIOVASCULAR RISK IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WITH OR WITHOUT METABOLIC SYNDROME
    Millan, J.
    Garcia Calzado, C.
    Recarte, C.
    ATHEROSCLEROSIS SUPPLEMENTS, 2011, 12 (01) : 29 - 29
  • [22] Cardiovascular risk in patients with diabetes type 2 with or without associated metabolic syndrome
    Munoz Roldan, Inmaculada
    Martin Puig, Maria Belen
    Agudo Villa, Maria Teresa
    Garcia Andrade, Carlos Recarte
    Millan Nunez-Cortes, Jesus
    CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2011, 23 (03): : 112 - 118
  • [23] Fenofibrate for Cardiovascular Disease Prevention in Metabolic Syndrome and Type 2 Diabetes Mellitus
    Steiner, George
    AMERICAN JOURNAL OF CARDIOLOGY, 2008, 102 (12A): : 28L - 33L
  • [24] Metabolic Syndrome Model Definitions Predicting Type 2 Diabetes and Cardiovascular Disease
    Povel, Cecile M.
    Beulens, Joline W.
    van der Schouw, Yvonne T.
    Dolle, Martijn E. T.
    Spijkerman, Annemieke M. W.
    Verschuren, W. M. Monique
    Feskens, Edith J. M.
    Boer, Jolanda M. A.
    DIABETES CARE, 2013, 36 (02) : 362 - 368
  • [25] Cardiovascular risk modification after combined intervention of rosiglitazone and exercise in patients with type 2 diabetes mellitus and metabolic syndrome
    Kadoglou, N.
    Iliadis, F.
    Angelopoulou, N.
    Liapis, C.
    Perrea, D.
    Alevizos, M.
    DIABETOLOGIA, 2006, 49 : 71 - 72
  • [26] Exercise training to reduce cardiovascular risk in patients with metabolic syndrome and type 2 diabetes mellitus: How does it work?
    Kraenkel, Nicolle
    Bahls, Martin
    Van Craenenbroeck, Emeline M.
    Adams, Volker
    Serratosa, Luis
    Solberg, Erik Ekker
    Hansen, Dominique
    Doerr, Marcus
    Kemps, Hareld
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2019, 26 (07) : 701 - 708
  • [27] Metabolic syndrome risk for cardiovascular disease and diabetes in the ARIC study
    C M Ballantyne
    R C Hoogeveen
    A M McNeill
    G Heiss
    M I Schmidt
    B B Duncan
    J S Pankow
    International Journal of Obesity, 2008, 32 : S21 - S24
  • [28] Metabolic syndrome risk for cardiovascular disease and diabetes in the ARIC study
    Ballantyne, C. M.
    Hoogeveen, R. C.
    McNeill, A. M.
    Heiss, G.
    Schmidt, M. I.
    Duncan, B. B.
    Pankow, J. S.
    INTERNATIONAL JOURNAL OF OBESITY, 2008, 32 (Suppl 2) : S21 - S24
  • [29] Metabolic syndrome and subsequent risk of type 2 diabetes and cardiovascular disease in elderly women: Challenging the current definition
    Dragsbaek, Katrine
    Neergaard, Jesper S.
    Laursen, Janne M.
    Hansen, Henrik B.
    Christiansen, Claus
    Beck-Nielsen, Henning
    Karsdal, Morten A.
    Brix, Susanne
    Henriksen, Kim
    MEDICINE, 2016, 95 (36)
  • [30] Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk
    Stalenhoef, A. F. H.
    Davidson, M. H.
    Robinson, J. G.
    Burgess, T.
    Duttlinger-Maddux, R.
    Kallend, D.
    Goldberg, A. C.
    Bays, H.
    DIABETES OBESITY & METABOLISM, 2012, 14 (01): : 30 - 39